Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Charles River Labs and PathoQuest Expand Biologics Partnership

By Charles River Laboratories International, Inc. | April 10, 2018

Charles River Laboratories and PathoQuest are expanding their strategic partnership agreement to provide next-generation sequencing (NGS) services to the biologics industry. As part of the expanded partnership, Charles River intends to make a direct investment in PathoQuest.

“Our partnership with PathoQuest is integral to our ability to provide the most sensitive testing methods to our clients in order to ensure the safety of biological products produced by the biopharmaceutical industry,” said Greg Beattie, corporate vice president, Global Biologics Testing Solutions at Charles River. “PathoQuest’s NGS-based testing solution provides a comprehensive analysis that is both rapid and reliable.”

Since 2016, Charles River has provided clients access to PathoQuest’s NGS solution, which combines a proprietary sample preparation method, state-of-the-art equipment, and an exclusive curated pathogen database with a comprehensive BioIT analysis pipeline. PathoQuest’s NGS solution is a powerful test for identifying adventitious agents in a single, comprehensive analysis that minimizes false negatives while also providing a tool for the genetic characterization of cell lines.

“Industry guidelines increasingly identify High-Throughput Sequencing, also known as NGS, as a highly sensitive and reliable testing solution,” said Jean-François Brepson, president and CEO of PathoQuest. “We anticipate Charles River’s global footprint and biologics-industry leadership will enable the further growth and expansion of our platform.”

The combination of Charles River’s existing GLP and GMP capabilities and PathoQuest’s unique offering allows for a fully integrated, rapid, and reliable solution for the testing of vaccines, biologics, and gene therapy products.

(Source: Charles River Laboratories International, Inc.)

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE